micronavigation EUTOS path item About the cooperation

About the cooperation

Dear Colleagues

The European LeukemiaNet (ELN) and Novartis have launched a collaboration committed to improving the understanding and treatment of chronic myeloid leukemia (CML) – the European Outcome and Treatment Study for CML (EUTOS). After three years of fruitful collaboration, the partnership has been renewed for two additional years (2011-2012). Uniting the expertise of the ELN and Novartis, the objectives of the collaboration are to gain a real-world pan-European picture of the incidence, distribution and outcomes of CML, and to inform and encourage improved management of the disease among healthcare professionals. These aims will be achieved by encouraging uptake of guidelines for the treatment of CML issued by the ELN in 2006 and updated in 2009, and by investigating the effects of treatments of patients across Europe.

The ELN represents 182 academic institutions, and unites over 1000 researchers in 34 countries, with the aim of research collaboration to make leukemia a curable disease. The ELN is committed to conducting clinical research and providing guidance to healthcare professionals about all types of leukemia, and CML is a key priority. The collaboration with Novartis, a company with a strong heritage in this field, has enabled a number of pan-European initiatives that will not only define best practice in the monitoring of patients with CML, but also deliver important advances in the understanding and treatment of this serious disease.

A key activity of the collaboration is the extension of the ELN registry – a database that follows CML patients and provides a real-world picture of their treatment and outcomes – into a pan-European study. This important initiative will provide a clear picture of the current management of CML, and will inform future guidance provided to physicians by the ELN.

Monitoring services will be made available to physicians treating patients with CML, providing free access to state-of-the-art technology that can assess patients’ response to treatment focusing on progressively deeper degrees of detection (MMR and CMR).,..

Educational initiatives providing physicians high-quality medical education to improve understanding and treatment of CML and resources that support them in caring for patients with CML.
Professor Hehlmann - Coordinator of the ELN
Guido Guidi - Head Region Europe Novartis Oncology, Novartis


Created by: Hellenbrecht , generated 2008/01/24 , last changed: 2011/05/12


Print this Document Sitemap   Contact  
European LeukemiaNet More ...